TargetBeta
GHR
growth hormone receptor · also GHBP · Fibronectin type III domain containing
2 programs in company-led studies act on GHR, from 2 companies: 1 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Acts as | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|---|
| Human Growth Hormonerule | Novo Nordisk | agonist | phase 4 | 1185 running | – | ChEMBL |
| lonapegsomatropinrule | Ascendis Pharma Endocrinology Division | agonist | phase 3 | 63 running | – | ChEMBL |
Conditions their studies are in
- Dwarfism, Pituitary, 2 programs
- Turner Syndrome, 2 programs
- Achondroplasia, 1 program
- Dwarfism, 1 program
- Genetic Diseases, Inborn, 1 program
- Growth Disorders, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Apr 28, 2027Human Growth Hormone · Novo Nordisk · phase 4 · NCT07691125
- Feb 2028lonapegsomatropin · Ascendis Pharma Endocrinology Division · phase 3 · NCT07221851
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.